Last reviewed · How we verify
NCT05924152
A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib
Phase 1 trial testing Adagrasib in Healthy Adults in 16 participants. Completed in 17 August 2023.
9 August 2023
Quick facts
| Lead sponsor | Mirati Therapeutics Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | other |
| Enrollment | 16 |
| Start date | 29 June 2023 |
| Primary completion | 9 August 2023 |
| Estimated completion | 17 August 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Adagrasib (ADAGRASIB) — full drug profile →
- Eltrombopag + adagrasib — full drug profile →
Conditions studied
- Healthy Adults — all drugs for Healthy Adults →
Sponsor
Mirati Therapeutics Inc. — full company profile →
Who can join
Adults 18 to 60, any sex, with Healthy Adults. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Phase 1, Open-label, One-sequence Crossover Study to Investigate the Effect of a Breast Cancer Resistance Protein Inhibitor on the Single-dose Pharmacokinetics of Adagrasib in Healthy Adult Subjects
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05924152
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Adagrasib
Trials testing the same drug.
- NCT07382726 — Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial · Phase 1 · not yet recruiting
- NCT07318389 — ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer · EARLY_PHASE1 · not yet recruiting
- NCT07415031 — A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies · Phase 2 · not yet recruiting
- NCT07288034 — Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatmen · Phase 2 · recruiting
- NCT06875310 — A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participan · Phase 3 · recruiting
Other recruiting trials for Healthy Adults
Currently open trials in the same condition.
- NCT07454551 — The Comparison of Different Passive Warm-Up Methods Prior to Exercise · NA · recruiting
- NCT07431853 — A Study to Learn About mRNA Vaccines Against Influenza in Adults · Phase 2 · recruiting
- NCT07362550 — Effects of 12-Week Balanced Diet on Body Composition & Metabolic Parameters in Twins · NA · recruiting
- NCT07284173 — A Study to Learn if a Medicine That Reduces Stomach Acid Affects the Blood Level of Study Medicine PF-08049820 in Health · Phase 1 · active not recruiting
- NCT07518758 — Acute Effect of Polyphenols Supplementation on Endothelial Function and Exercise Related Markers, in Physically Active H · NA · active not recruiting
Other Mirati Therapeutics Inc. trials
Trials by the same sponsor.
- NCT07415031 — A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies · Phase 2 · not yet recruiting
- NCT06875310 — A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participan · Phase 3 · recruiting
- NCT06801418 — Bioequivalence Study Between Adagrasib Reference Tablets and High Drug Load Tablets · Phase 1 · completed
- NCT05853575 — Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) · Phase 2 · active not recruiting
- NCT05840510 — Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a · Phase 1 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05924152 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mirati Therapeutics Inc.
- Last refreshed: 13 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05924152.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing